TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20448031

Group type: EXPERIMENTAL
Intervention: Resistance training of the plantar flexor muscles (15 sessions of unilateral mainly eccentric plantar flexor exercise over a 5‐wk period)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance training of the plantar flexor muscles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 20
Study: 17097834

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT)
Number of subjects: 227

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 227
Study: 16049121

Group type: EXPERIMENTAL
Intervention: 1-hour walk in natural surroundings
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and nonintervention)
Number of subjects: 33
Study: 12861790

Group type: EXPERIMENTAL
Intervention: Deep diaphragmatic breathing technique
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Focused attention technique
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no specific technique mentioned)
Number of subjects: 272
Study: 10394524

Group type: EXPERIMENTAL
Intervention: Mechanical assisted hatching (AH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8878217

Group type: EXPERIMENTAL
Intervention: 5 micrograms Engerix-B vaccine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 micrograms Engerix-B vaccine
Number of subjects: 153
Study: 2049750

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus prednisolone (PRDLN) (5 mg twice daily)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) (10 mg twice daily) plus placebo
Number of subjects: 326
Study: 6504421

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 70
Study: 30723140

Group type: EXPERIMENTAL
Intervention: Letrozole plus Alpelisib (2.5 mg/day letrozole with 300 mg/day alpelisib for 24 weeks)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo (for 24 weeks)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Letrozole plus Alpelisib
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 27654902

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation + Supported Employment (CR + SE)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Traditional Vocational Services (TVS)
Number of subjects: 111
Study: 26271753

Group type: EXPERIMENTAL
Intervention: Bubble CPAP (B)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Flow Driver CPAP (FD)
Number of subjects: 125
Study: 25143506

Group type: EXPERIMENTAL
Intervention: Concentric glenosphere
Number of subjects: 50

Group type: COMPARATOR
Intervention: Eccentric glenosphere
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 22623022

Group type: EXPERIMENTAL
Intervention: Placebo pill
Number of subjects: 141
Study: 19389019

Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin-A (BTX-A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17931925

Group type: EXPERIMENTAL
Intervention: 1.8 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 65

Group type: COMPARATOR
Intervention: 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both bupivacaine and lidocaine
Number of subjects: 65
Study: 15826236

Group type: EXPERIMENTAL
Intervention: Smooth pursuit eye movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Items stabilized on the retina moving with the pursuit target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miniature items presented on the pursuit target
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smooth pursuit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eye fixation
Number of subjects: 0
Study: 11339921

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 9462439

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg iv tds for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg iv bd for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Number of subjects: 628
Study: 8170877

Group type: EXPERIMENTAL
Intervention: Intravenous heparin and nitroglycerin (GTN) at a constant dose of 16.6 micrograms/minute
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous heparin and isosorbide dinitrate at a constant dose of 33.3 micrograms/minute
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups received identical doses of heparin
Number of subjects: 50
Study: 2947874

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29474893

Group type: EXPERIMENTAL
Intervention: Personalized bronchodilator dosing
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fixed bronchodilator dosing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 26105554

Group type: EXPERIMENTAL
Intervention: 24-week progressive resistance training (PRT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance exercise (acute effect)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 24769306

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study: 23875907

Group type: EXPERIMENTAL
Intervention: Modulation group (catheter inversion technique for concave aspect, prominent Eustachian ridge, steep angle of the CTI)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Nonmodulation group (conventional strategy)
Number of subjects: 446
Study: 21397720

Group type: EXPERIMENTAL
Intervention: HBV vaccine with GM-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: HBV vaccine without GM-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline progenitor cell frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline monocyte frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM-CSF receptor expression
Number of subjects: 0
Study: 18286870

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (long-term use)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HIV control group)
Number of subjects: 99
Study: 16545330

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (150 microg Nestorone and 15 microg ethinyl estradiol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Stediril 30 (oral contraceptive containing levonorgestrel)
Number of subjects: 45
Study: 12677155

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 279

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 279
Study: 11261274

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose consolidation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 0
Study: 9171464

Group type: EXPERIMENTAL
Intervention: Leg exercise during decompression
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Arm exercise during decompression
Number of subjects: 29

Group type: COMPARATOR
Intervention: Inactive controls
Number of subjects: 29
Study: 1608898

Group type: EXPERIMENTAL
Intervention: Pulsatile delivery system for captopril
Number of subjects: 8
Study: 6282024

Group type: EXPERIMENTAL
Intervention: Captopril (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30315394

Group type: EXPERIMENTAL
Intervention: iRBD patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 29394175

Group type: COMPARATOR
Intervention: Sham stimulation (n = 10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-frequency (1‐Hz) stimulation of the nonaffected hemisphere (n = 11)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-frequency (10‐Hz) stimulation of the affected hemisphere (n = 13)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sequential combination of low‐ and high‐frequency stimulations (n = 8)
Number of subjects: 42
Study: 27032884

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection after ESD
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (ESD only)
Number of subjects: 67
Study: 24395980

Group type: EXPERIMENTAL
Intervention: β-blocker treatment
Number of subjects: 3019

Group type: COMPARATOR
Intervention: Not treated with β-blockers
Number of subjects: 3019
Study: 21383686

Group type: EXPERIMENTAL
Intervention: Upfront therapy for aGVHD
Number of subjects: 83

Group type: COMPARATOR
Intervention: No response to therapy by day 28
Number of subjects: 83
Study: 19444142

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 396

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 396

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Aliskiren-based therapy
Number of subjects: 396
Study: 17464949

Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (12 g/m(2)/cycle)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard-dose ifosfamide (6 g/m(2)/cycle)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (ERMBT)
Number of subjects: 22
Study: 17130195

Group type: EXPERIMENTAL
Intervention: Internet-based glucose monitoring system (IBGMS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional office visits
Number of subjects: 80
Study: 12762613

Group type: EXPERIMENTAL
Intervention: Open sandwich restoration using resin modified glass ionomer (Fuji II LCor Photac‐Fil) and microhybrid flowable composite (Aeliteflo or Flow‐it)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional amalgam (Tytin) restorations
Number of subjects: 0
Study: 10786226

Group type: EXPERIMENTAL
Intervention: Urinary beta-hexosaminidase determinations in patients on methadone substitution
Number of subjects: 0
Study: 8730122

Group type: EXPERIMENTAL
Intervention: rIFN-gamma 0.01 mg/m2/day for 1 week, followed by 0.1 mg/m2/day intramuscularly for 18 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 20
Study: 1831629

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study: 7091876

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29986717

Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP)
Number of subjects: 3151

Group type: COMPARATOR
Intervention: Rapid diagnostic tests (RDTs)
Number of subjects: 3151

Group type: EXPERIMENTAL
Intervention: LAMP on collected RDTs
Number of subjects: 3151
Study: 25545309

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 74

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 74
Study: 23138883

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 39
Study: 21239519

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (10 mg) with GH (0.6 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral testosterone (40 mg) with GH (0.6 mg/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: GH therapy alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Transdermal testosterone (10 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral testosterone (40 mg)
Number of subjects: 11
Study: 18268144

Group type: EXPERIMENTAL
Intervention: PCI + OMT
Number of subjects: 314

Group type: COMPARATOR
Intervention: OMT
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Patients with ischemia reduction
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Patients with moderate to severe baseline ischemia
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Patients with no residual ischemia
Number of subjects: 314
Study: 16344520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Subset 1 predictors (age at disease onset, disease duration, sex, EDSS at baseline, number of relapses in the last 24 months, disease course)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Subset 2 predictors (Subset 1 plus gadolinium enhancement status)
Number of subjects: 821
Study: 12528101

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg plus MTX
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg plus MTX
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg plus MTX
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 271
Study: 10816895

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8899499

Group type: EXPERIMENTAL
Intervention: IFN-alpha, 16 million U1 intramuscularly daily for 2 weeks, then three times a week
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IFN-alpha, 24 weeks treatment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IFN-alpha, 40 weeks treatment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IFN-alpha, long-term treatment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IFN-alpha, treatment for HCV-RNA genotype 1b and 2a or 2b
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IFN-alpha, 40 weeks treatment for patients with mild liver tissue damage or low virus counts
Number of subjects: 136
Study: 2056598

Group type: EXPERIMENTAL
Intervention: 11 ml 2% lidocaine jelly
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 20 ml 2% lidocaine jelly
Number of subjects: 241
Study: 6409634

Group type: EXPERIMENTAL
Intervention: Low fat diet (22% of energy as total fat, 4% as polyunsaturated fatty acids)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Moderate fat diet (30% of energy as total fat; 11% as polyunsaturated fatty acids)
Number of subjects: 95
Study: 31653228

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 524

Group type: COMPARATOR
Intervention: Consultation liaison
Number of subjects: 524
Study: 27864694

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks for the first 6 of 8 cycles and for 10 doses postoperatively)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Control (no bevacizumab)
Number of subjects: 1206
Study: 26016168

Group type: EXPERIMENTAL
Intervention: Prewarming (group A, n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No prewarming (group B, n = 22)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BMI below 25
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BMI above 25
Number of subjects: 43
Study: 24903511

Group type: EXPERIMENTAL
Intervention: Atorvastatin reload
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 22533496

Group type: EXPERIMENTAL
Intervention: Bedtime dose of ARB
Number of subjects: 109

Group type: COMPARATOR
Intervention: Morning dose of ARB
Number of subjects: 109
Study: 18708615

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/d
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study: 17575470

Group type: EXPERIMENTAL
Intervention: 12‐week treadmill exercise program (target lactate 2.5 +/‐ 0.5 mmol/l)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 54
Study: 15220227

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin aspart
Number of subjects: 32

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with once-daily glargine and premeal/snack insulin aspart
Number of subjects: 32
Study: 11353429

Group type: EXPERIMENTAL
Intervention: Concentric needle electrode (CNE) (diameter = 0.46 mm)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Monopolar needle electrode (MNE) (diameter = 0.41 mm)
Number of subjects: 90
Study: 9142019

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (n = 179)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Physician-directed weaning (n = 178)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 357

Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 357
Study: 7911266

Group type: EXPERIMENTAL
Intervention: Sizofilan (SPG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 3316061

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29435758

Group type: EXPERIMENTAL
Intervention: Multi-modality Training (12 hours of training on Virtual Reality and box trainer)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multi-modality Training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Junior residents (Training)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Senior residents
Number of subjects: 64
Study: 26358375

Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 46
Study: 25219946

Group type: EXPERIMENTAL
Intervention: Ayushman-15A
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ayushman-15B
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 81
Study: 23699508

Group type: EXPERIMENTAL
Intervention: Reduced prefrontal inhibitory regulation in short-allele (s) carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homozygous long-allele carriers
Number of subjects: 0
Study: 21169170

Group type: EXPERIMENTAL
Intervention: 8-week therapist-assisted Web-based treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: 8-week attention-placebo intervention
Number of subjects: 106
Study: 17711615

Group type: EXPERIMENTAL
Intervention: Case formulation (CF) in cognitive behaviour therapy
Number of subjects: 13
Study: 16802254

Group type: EXPERIMENTAL
Intervention: Combined cardiorespiratory and resistance exercise training program (8-week, 3 sessions per week, 90 minutes each)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control non-exercising group
Number of subjects: 16
Study: 14616330

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (O4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV (O8)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline) (P)
Number of subjects: 90
Study: 10819278

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (500,000 KIU)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Medium-dose aprotinin (1,000,000 KIU load, 250,000 KIU/hr infusion)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2,000,000 KIU load, 500,000 KIU/hr infusion)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Aprotinin (all doses combined)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 9092709

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegic solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cold blood cardioplegic solution
Number of subjects: 35
Study: 8442967

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg diluted in 10 ml saline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Epidural lidocaine (10 ml of 2% lidocaine)
Number of subjects: 16
Study: 3522818

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlorpromazine (CLP)
Number of subjects: 50
Study: 31862447

Group type: EXPERIMENTAL
Intervention: Surgical procedure for treatment of intermittent exotropia in children aged 3 to <5 years.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Surgical procedure for treatment of intermittent exotropia in children aged 5 to <11 years.
Number of subjects: 197
Study: 31509993

Group type: EXPERIMENTAL
Intervention: Human Animal Interaction with therapy dogs only (100% HAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equal combinations of Academic Stress Management and HAI (50% HAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evidence‐based Academic Stress Management content only (0% HAI)
Number of subjects: 0
Study: 27339738

Group type: EXPERIMENTAL
Intervention: obinutuzumab or rituximab induction therapy (IT) for 4 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PET-positive after IT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PET assessment using Deauville five-point scale criteria
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Change in standardized uptake value and other PET parameters
Number of subjects: 75
Study: 25547339

Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 238
Study: 23797811

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Number of subjects: 132

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 132
Study: 19736173

Group type: EXPERIMENTAL
Intervention: MyWellness Key accelerometer
Number of subjects: 16
Study: 19444558

Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol group (F-P group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline-propofol group (S-P group)
Number of subjects: 59
Study: 16713991

Group type: EXPERIMENTAL
Intervention: Group KM: KT program with 6-month weight and targeted behavior's self-monitoring
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Group K: KT program only
Number of subjects: 205

Group type: COMPARATOR
Intervention: Group BM: untailored self-help booklet with 7-month self-monitoring of weight and walking
Number of subjects: 205

Group type: COMPARATOR
Intervention: Group B: self-help booklet only
Number of subjects: 205